Shivali Gulab

Chief Executive Officer, Avalia Immunotherapies

New York-based, Dr Shivali Gulab has over twelve years experience in research, the development of pre­clinical assets and partnering of novel candidates developed by leading research groups in NZ and the USA.

In her business development, commercialisation and strategic partnership roles, she has routinely led negotiations with global partners that generate successful partnerships, services contracts and deliver pre­clinical assets targeting a range of cancer and infectious disease indications.

Following her PhD, she was a Research Scientist at the Ferrier Research Institute, working on the synthesis of enzyme inhibitors and immune modulators for various indications, followed by a role as visiting scientist at Albert Einstein College of Medicine, New York.

She is a named inventor on granted US patents, which have resulted in significant returns to the licensee. Dr Gulab completed a PhD in Chemistry at Victoria University of Wellington and was named NZ Bio’s Young Scientist of the Year in 2015.